Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma

[Business Wire] – Bristol-Myers Squibb Company , Pharmacyclics, Inc. , and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and . . . → Read More: Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S. Stock Update (NYSE:BMY): Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo (nivolumab) in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer (NSCLC) Company Update (NYSE:BMY): Bristol-Myers Squibb to Announce Results for Third Quarter on October 24
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.